Get the Stockscreener App
2.445
11.09%
-0.305
After Hours:
2.60
0.155
+6.34%
Editas Medicine Inc stock is traded at $2.445, with a volume of 2.45M.
It is down -11.09% in the last 24 hours and down -9.44% over the past month.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
See More
Previous Close:
$2.75
Open:
$2.73
24h Volume:
2.45M
Relative Volume:
0.92
Market Cap:
$375.50M
Revenue:
$38.69M
Net Income/Loss:
$-108.95M
P/E Ratio:
-2.00
EPS:
-1.2225
Net Cash Flow:
$-141.09M
1W Performance:
-10.44%
1M Performance:
-9.44%
6M Performance:
-23.59%
1Y Performance:
-31.32%
1-Day Range:
$2.44
$2.73
1-Week Range:
$2.44
$2.97
52-Week Range:
$1.66
$4.33
Editas Medicine Inc Stock (EDIT) Company Profile
Name
Editas Medicine Inc
Sector
Industry
Phone
617-401-9000
Address
11 HURLEY ST., CAMBRIDGE, MA
Compare EDIT vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
2.445 | 375.50M | 38.69M | -108.95M | -141.09M | -1.2225 |
VRTX
Vertex Pharmaceuticals Inc
|
485.22 | 122.98B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
216.25 | 86.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
753.12 | 77.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.64 | 50.47B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.44 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-26 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-23-26 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-18-26 | Initiated | Ladenburg Thalmann | Buy |
| Apr-28-25 | Initiated | H.C. Wainwright | Buy |
| Dec-16-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-13-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Dec-13-24 | Downgrade | Stifel | Buy → Hold |
| Dec-13-24 | Downgrade | Truist | Buy → Hold |
| Dec-11-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-25-24 | Downgrade | BofA Securities | Buy → Underperform |
| Nov-06-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-04-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Aug-08-24 | Upgrade | BofA Securities | Neutral → Buy |
| May-09-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Oct-24-23 | Upgrade | Citigroup | Neutral → Buy |
| Oct-18-23 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-17-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-29-23 | Upgrade | Stifel | Hold → Buy |
| Jun-12-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-13-22 | Initiated | Citigroup | Neutral |
| Dec-06-22 | Resumed | Credit Suisse | Neutral |
| Nov-18-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-18-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-29-22 | Initiated | BofA Securities | Neutral |
| Oct-19-21 | Initiated | SVB Leerink | Mkt Perform |
| Sep-24-21 | Initiated | Stifel | Hold |
| Sep-10-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-09-21 | Upgrade | Truist | Hold → Buy |
| Aug-05-21 | Upgrade | Evercore ISI | Underperform → Outperform |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Apr-16-21 | Initiated | Goldman | Sell |
| Mar-22-21 | Initiated | Credit Suisse | Outperform |
| Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-26-21 | Downgrade | Truist | Buy → Hold |
| Jan-19-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-07-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-10-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-03-20 | Initiated | Robert W. Baird | Underperform |
| Jun-18-20 | Resumed | SunTrust | Buy |
| Feb-21-20 | Initiated | Wells Fargo | Equal Weight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Oct-10-18 | Initiated | Guggenheim | Neutral |
| Sep-21-18 | Initiated | Raymond James | Outperform |
| May-15-18 | Reiterated | Chardan Capital Markets | Buy |
| Feb-13-18 | Initiated | CLSA | Underperform |
| Jan-23-18 | Upgrade | SunTrust | Hold → Buy |
| Jul-14-17 | Initiated | SunTrust | Hold |
| Mar-28-17 | Initiated | Chardan Capital Markets | Buy |
| Aug-10-16 | Upgrade | Jefferies | Hold → Buy |
| Jun-02-16 | Initiated | Jefferies | Hold |
| Feb-29-16 | Initiated | JMP Securities | Mkt Outperform |
| Feb-29-16 | Initiated | JP Morgan | Neutral |
| Feb-29-16 | Initiated | Morgan Stanley | Equal-Weight |
View All
Editas Medicine Inc Stock (EDIT) Latest News
EDIT Set to Begin First-in-Human Study in Hypercholesterolemia - Zacks Investment Research
Editas Medicine (NasdaqGS:EDIT) Stock Forecast & Analyst Predictions - Simply Wall Street
Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy - Yahoo Finance
Opaleye Management Inc. Buys 1,934,933 Shares of Editas Medicine, Inc. $EDIT - MarketBeat
EDIT: EDIT-401 targets up to 90% LDL reduction, with first patient dosing on track for this year - TradingView
Editas Medicine at Cantor conference: in vivo CRISPR push advances - Investing.com
Editas Medicine (NASDAQ: EDIT) Grants 950,000 Derivative Securities to CMO Ory Daniel Scott on September 8, 2026 - Kalkine Media
Editas Medicine, Inc. (NASDAQ:EDIT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Editas Medicine (NASDAQ: EDIT) awards options vesting through 2030 to its CMO - Stock Titan
Editas Medicine (NASDAQ: EDIT) CMO named as reporting insider - Stock Titan
Editas Medicine grants stock options to new chief medical officer - investing.com
Editas Medicine grants stock options to new chief medical officer By Investing.com - Investing.com Australia
Editas Medicine grants stock options to new chief medical officer By Investing.com - Investing.com Nigeria
Editas Medicine grants stock options to new chief medical officer By Investing.com - Investing.com Canada
Editas Medicine grants stock options to new chief medical officer By Investing.com - Investing.com India
Editas Medicine grants stock options to new chief medical officer By Investing.com - Investing.com UK
New medical chief can earn the right to buy 950,000 Editas shares - Stock Titan
Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401 - MarketBeat
Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401 - Yahoo Finance
Editas Medicine, Inc. SEC Filing (Sep 9, 2026) - Stock Titan
Editas Medicine Reports Inducement Grants to New Chief Medical Officer - GlobeNewswire
Editas Medicine Reports Inducement Grants to New Chief Medical Officer - Yahoo Finance
Editas Medicine names Dan Ory as chief medical officer By Investing.com - Investing.com South Africa
EDIT: EDIT-401 aims for unprecedented LDL reduction, with first human data expected in 2027 - TradingView
Editas Medicine at Wells Fargo conference: a focused bet on CRISPR By Investing.com - Investing.com India
Editas Medicine at Wells Fargo conference: a focused bet on CRISPR - Investing.com
Editas Medicine at Wells Fargo conference: a focused bet on CRISPR - Investing.com UK
Editas Medicine CFO Parison Amy Retains 13,839 Shares After Selling 453 at $3.04 Each - Kalkine Media
Editas Medicine Appoints Dan Ory as Chief Medical Officer - citybiz
Editas Medicine names Dan Ory as chief medical officer By Investing.com - Investing.com Nigeria
Editas Medicine names Dan Ory as chief medical officer By Investing.com - Investing.com Canada
A potential gene-editing treatment moves toward trials as Editas adds a veteran with more than 25 years' experience. - Stock Titan
Editas Medicine names Dan Ory as chief medical officer - Investing.com
Editas Medicine names Dan Ory as chief medical officer By Investing.com - Investing.com UK
Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer - GlobeNewswire Inc.
Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer - The National Law Review
Seven Fleet Capital Management LP Takes Position in Editas Medicine, Inc. $EDIT - MarketBeat
Editas Medicine CSO Linda Burkly Sells 709 Shares to Cover RSU Tax Withholding - Kalkine Media
Editas Medicine (NASDAQ:EDIT) CEO Gilmore Neil O'neill Sells 5,124 Shares of Stock - MarketBeat
Editas Medicine CFO Amy Parison Sells Shares in September 2026 Under Pre-Set Plan - kalkinemedia.com
Editas Medicine CEO Gilmore Neil O'Neill Sells 5,124 Shares to Cover Tax Withholding on RSU Vesting - kalkinemedia.com
Editas Medicine (EDIT) CSO stock sale follows tax plan - Stock Titan
Pre-set plan triggers Editas (NASDAQ: EDIT) CFO share sale - Stock Titan
Editas Medicine (NASDAQ: EDIT) CEO sells 5,124 shares in tax-plan trade - Stock Titan
Editas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Editas Medicine (EDIT) Slides 1.3% to $3.04 as Support Level Comes into FocusRetracement Entry - vinanet.vn
Editas Medicine (EDIT) Slides 1.3% to $3.04 as Support Level Comes into FocusGamma Squeeze - siam.in
EditasSlow Progress Doesn't Mean No Progress For In-Vivo Gene Editor (NASDAQ:EDIT) - Seeking Alpha
BlackRock Inc. Takes Position in Editas Medicine, Inc. $EDIT - MarketBeat
Boston and New York will host Editas Medicine talks this month - stocktitan.net
Editas Medicine Inc Stock (EDIT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Editas Medicine Inc Stock (EDIT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Parison Amy | SVP, Chief Financial Officer |
Sep 03 '26 |
Sale |
3.04 |
453 |
1,376 |
13,839 |
| O'Neill Gilmore Neil | CEO |
Sep 03 '26 |
Sale |
3.04 |
5,124 |
15,563 |
243,189 |
| O'Neill Gilmore Neil | Officer |
Sep 03 '26 |
Proposed Sale |
3.28 |
5,100 |
16,728 |
0 |
| Burkly Linda | Officer |
Sep 03 '26 |
Proposed Sale |
3.28 |
700 |
2,296 |
0 |
| Parison Amy | SVP, Chief Financial Officer |
Aug 03 '26 |
Sale |
2.58 |
678 |
1,749 |
14,292 |
| Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER |
Jul 28 '26 |
Sale |
2.67 |
4,928 |
13,158 |
62,369 |
| Burkly Linda | Officer |
Jul 27 '26 |
Proposed Sale |
2.88 |
5,500 |
15,840 |
0 |
| Parison Amy | SVP, Chief Financial Officer |
Jun 03 '26 |
Sale |
2.70 |
464 |
1,253 |
14,970 |
| O'Neill Gilmore Neil | CEO |
Jun 03 '26 |
Sale |
2.70 |
15,380 |
41,543 |
248,313 |
| Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER |
Jun 03 '26 |
Sale |
2.70 |
731 |
1,975 |
67,297 |
4.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):